In its most recent 13F filing with the Securities and Exchange Commission, Commerzbank Aktiengesellschaft FI disclosed a 30.5 percent reduction in its stake in AbbVie. The firm sold 39,586 shares during the third quarter, bringing its total holding to 90,102 shares valued at approximately 20.863 million at period end. This move follows broader institutional activity in AbbVie, with other large investors such as Norges Bank and Vanguard Group adjusting positions by billions of dollars in aggregate.

AbbVie reported third-quarter earnings per share of 1.86, outpacing the consensus estimate of 1.77 by 0.09, while quarterly revenue of 15.78 billion topped expectations of 15.58 billion and represented a 9.1 percent year-over-year increase. The company’s net margin stood at 4.0 percent, and return on equity reached 3,216 percent. Management raised Q4 EPS guidance to a range of 3.320 to 3.360 and reiterated an expected full-year EPS of 12.31, reflecting confidence in pipeline momentum and core product performance.

AbbVie declared a quarterly dividend of 1.73 per share, payable February 17 to shareholders of record as of January 16. The new dividend represents a 5.5 percent increase over the prior payout of 1.64, translating to an annualized distribution of 6.92 and a yield of 3.2 percent based on recent share counts. This marks the company’s 14th consecutive annual dividend hike since its 2013 spin-off, underscoring its commitment to returning capital to shareholders.